Charles Schwab
AQST icon

Charles Schwab’s Aquestive Therapeutics AQST Stock Holding History

Charles Schwab’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
306,394
+38,975
+15% +$164K ﹤0.01% 2931
2026
Q1 		$1.11M Sell
267,419
-34,102
-11% -$138K ﹤0.01% 2873
2025
Q4 		$1.95M Buy
301,521
+47,350
+19% +$295K ﹤0.01% 2761
2025
Q3 		$1.42M Buy
254,171
+9,775
+4% +$42.3K ﹤0.01% 2842
2025
Q2 		$809K Buy
244,396
+33,697
+16% +$96.7K ﹤0.01% 2967
2025
Q1 		$611K Buy
210,699
+30
+0% +$91 ﹤0.01% 3009
2024
Q4 		$750K Buy
210,669
+7,129
+4% +$32.9K ﹤0.01% 3011
2024
Q3 		$1.01M Buy
203,540
+9,268
+5% +$36.1K ﹤0.01% 2911
2024
Q2 		$505K Buy
194,272
+175,194
+918% +$585K ﹤0.01% 3193
2024
Q1 		$81.3K Hold
19,078
– – ﹤0.01% 3327
2023
Q4 		$38.5K Hold
19,078
– – ﹤0.01% 3427
2023
Q3 		$29.2K Hold
19,078
– – ﹤0.01% 3472
2023
Q2 		$31.5K Buy
+19,078
New +$34.5K ﹤0.01% 3497
2021
Q3 		– Sell
-74,757
Closed -$297K – 3503
2021
Q2 		$297K Sell
74,757
-97,940
-57% -$391K ﹤0.01% 3242
2021
Q1 		$899K Sell
172,697
-8,413
-5% -$44.8K ﹤0.01% 2895
2020
Q4 		$969K Hold
181,110
– – ﹤0.01% 2784
2020
Q3 		$880K Buy
181,110
+127,202
+236% +$831K ﹤0.01% 2706
2020
Q2 		$262K Buy
+53,908
New +$248K ﹤0.01% 3104
2019
Q2 		– Sell
-23,379
Closed -$162K – 3216
2019
Q1 		$162K Buy
+23,379
New +$164K ﹤0.01% 3052

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Charles Schwab's AQST Position: Q2 2026 in Review

Charles Schwab increased its Aquestive Therapeutics (AQST) stake by 15% in Q2 2026, buying an estimated $164K and bringing the position to 306,394 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2931.

Charles Schwab first reported a position in AQST in Q1 2019 and has held it in 19 quarters since. The position peaked at $1.95M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Charles Schwab held 306,394 shares of Aquestive Therapeutics worth $1.27M as of Q2 2026.
  • Charles Schwab bought 38,975 Aquestive Therapeutics shares in Q2 2026, an estimated $164K.
  • Aquestive Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2931 holding.
  • Charles Schwab first reported a position in Aquestive Therapeutics in Q1 2019 and has held it in 19 quarters since.
  • Charles Schwab's Aquestive Therapeutics position peaked at $1.95M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.